Breaking up may not be so hard to do: Despite taking lumps over rash of product recalls, Guidant remains strong, according to analysts
Guidant Corp. will be just fine if Johnson and Johnson walks away from its $25.4 billion purchase of the medicaldevice maker, Wall Street analysts say. Even so, the Indianapolis company would have to grapple with some tricky issues, they say, including quelling lingering product-safety concerns among doctors and stabilizing the executive ranks. Guidant has been battered by a series of product problems and recalls in recent months. On Oct. 18, it took another punch when J&J executive Robert Darretta told…